(VIANEWS) – Surgery Partners (SGRY), Medpace Holdings (MEDP), Erie Indemnity Company (ERIE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Surgery Partners (SGRY)
13.4% sales growth and 4.76% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Earnings Per Share
As for profitability, Surgery Partners has a trailing twelve months EPS of $0.01.
PE Ratio
Surgery Partners has a trailing twelve months price to earnings ratio of 2630. Meaning, the purchaser of the share is investing $2630 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.76%.
Volume
Today’s last reported volume for Surgery Partners is 74559 which is 91.47% below its average volume of 874630.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.7%, now sitting on 2.79B for the twelve trailing months.
Sales Growth
Surgery Partners’s sales growth is 10.1% for the ongoing quarter and 13.4% for the next.
Yearly Top and Bottom Value
Surgery Partners’s stock is valued at $26.30 at 11:22 EST, way below its 52-week high of $45.79 and way higher than its 52-week low of $22.05.
2. Medpace Holdings (MEDP)
12.9% sales growth and 61.35% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $9.83.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 41.27. Meaning, the purchaser of the share is investing $41.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.35%.
Sales Growth
Medpace Holdings’s sales growth is 14.7% for the ongoing quarter and 12.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 31.1% and 22.1%, respectively.
Moving Average
Medpace Holdings’s value is above its 50-day moving average of $393.99 and way higher than its 200-day moving average of $324.87.
3. Erie Indemnity Company (ERIE)
11.9% sales growth and 30.15% return on equity
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $9.26.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 38.17. Meaning, the purchaser of the share is investing $38.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.15%.
Moving Average
Erie Indemnity Company’s worth is below its 50-day moving average of $379.51 and above its 200-day moving average of $343.02.
Volume
Today’s last reported volume for Erie Indemnity Company is 56283 which is 20.12% below its average volume of 70467.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 14.2% and 4.4%, respectively.
4. Option Care Health (OPCH)
9.9% sales growth and 19.62% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Earnings Per Share
As for profitability, Option Care Health has a trailing twelve months EPS of $1.53.
PE Ratio
Option Care Health has a trailing twelve months price to earnings ratio of 18.45. Meaning, the purchaser of the share is investing $18.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.62%.
Sales Growth
Option Care Health’s sales growth is 9.5% for the current quarter and 9.9% for the next.
Volume
Today’s last reported volume for Option Care Health is 272051 which is 78.58% below its average volume of 1270460.
Moving Average
Option Care Health’s value is under its 50-day moving average of $30.25 and way under its 200-day moving average of $31.56.
Yearly Top and Bottom Value
Option Care Health’s stock is valued at $28.23 at 11:22 EST, way below its 52-week high of $35.74 and higher than its 52-week low of $26.17.
5. EZCORP (EZPW)
7.7% sales growth and 10.37% return on equity
EZCORP, Inc. provides pawn loans in the United States and Latin America. It offers pawn loans collateralized by tangible personal property, jewelry, consumer electronics, tools, sporting goods, and musical instruments. The company also sells merchandise, primarily collateral forfeited from pawn lending operations and pre-owned merchandise purchased from customers. In addition, it offers Lana and EZ+ web-based engagement platforms to manage pawn loans. As of September 30, 2021, the company owned and operated 516 pawn stores in the United States; 508 pawn stores in Mexico; and 124 pawn stores in Guatemala, El Salvador, and Honduras. EZCORP, Inc. was founded in 1989 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, EZCORP has a trailing twelve months EPS of $1.23.
PE Ratio
EZCORP has a trailing twelve months price to earnings ratio of 8.28. Meaning, the purchaser of the share is investing $8.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
Sales Growth
EZCORP’s sales growth for the next quarter is 7.7%.
Moving Average
EZCORP’s worth is below its 50-day moving average of $10.54 and above its 200-day moving average of $9.43.
Volume
Today’s last reported volume for EZCORP is 426449 which is 20.34% below its average volume of 535364.
6. Addus HomeCare Corporation (ADUS)
6.6% sales growth and 9.56% return on equity
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.
Earnings Per Share
As for profitability, Addus HomeCare Corporation has a trailing twelve months EPS of $4.02.
PE Ratio
Addus HomeCare Corporation has a trailing twelve months price to earnings ratio of 29.68. Meaning, the purchaser of the share is investing $29.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.56%.
Volume
Today’s last reported volume for Addus HomeCare Corporation is 103889 which is 16.5% below its average volume of 124425.
Yearly Top and Bottom Value
Addus HomeCare Corporation’s stock is valued at $119.30 at 11:22 EST, below its 52-week high of $119.98 and way higher than its 52-week low of $78.35.
Moving Average
Addus HomeCare Corporation’s value is way higher than its 50-day moving average of $106.14 and way above its 200-day moving average of $93.95.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 13.1% and 8.7%, respectively.
7. SS&C Technologies Holdings (SSNC)
5.1% sales growth and 10.14% return on equity
SS&C Technologies Holdings, Inc., together with its subsidiaries, provides software products and software-enabled services to financial services and healthcare industries. The company owns and operates technology stack across securities accounting; front-office functions, such as trading and modeling; middle-office functions comprising portfolio management and reporting; back-office functions, such as accounting, performance measurement, reconciliation, reporting, processing and clearing, and compliance and tax reporting; and healthcare solutions consisting of claims adjudication, benefit management, care management, and business intelligence solutions. Its products and services allow professionals in the financial services and healthcare industries to automate complex business processes and are instrumental in helping its clients to manage information processing requirements. The company's software-enabled services include SS&C GlobeOp, Global Investor and Distribution Solutions, SS&C Retirement Solutions, Black Diamond Wealth Platform, CRM Solutions, Advent Managed Services, Advent Data Solutions, ALPS Advisors, and Virtual Data Rooms, as well as pharmacy, healthcare administration, and health outcomes optimization solutions. Its software products comprise portfolio/investment accounting and analytics software, portfolio management software, trading software, automation solutions, and banking and lending solutions, as well as research, analytics, risk, and training solutions. The company also provides professional services that includes consulting and implementation services consisting of initial system installation, conversion of historical data, and ongoing training and support, as well as product support services. It operates in the United States; Europe, the Middle East, and Africa; the Asia Pacific and Japan; Canada; and the Americas. The company was founded in 1986 and is headquartered in Windsor, Connecticut.
Earnings Per Share
As for profitability, SS&C Technologies Holdings has a trailing twelve months EPS of $2.39.
PE Ratio
SS&C Technologies Holdings has a trailing twelve months price to earnings ratio of 25.95. Meaning, the purchaser of the share is investing $25.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.14%.
Volume
Today’s last reported volume for SS&C Technologies Holdings is 1825940 which is 90.81% above its average volume of 956934.
Sales Growth
SS&C Technologies Holdings’s sales growth is 5.1% for the ongoing quarter and 5.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 10.2% and 8.5%, respectively.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 3, 2024, the estimated forward annual dividend rate is 0.96 and the estimated forward annual dividend yield is 1.54%.
